Our aim is to set up and implement a MAMS platform trial, MASTODON-AD, which will, in its first phase, evaluate three leading drugs with proof-of-concept evidence in Alzheimer's Disease. The aim of this study is to carry out the initial preparatory work for this platform.

We will carry out a systematic drug selection process to identify the first three compounds to include in the platform. We will also finalise the set of outcome measures for the trial and complete trial design, including carrying out appropriate simulations. Each work package will be supported by dedicated PPIE (Patient and Public Involvement and Engagement).


For more information please see the PRE-MASTODON-AD trial page:

PRE-MASTODON-AD trial page